Project Grant DP2AI184554
Award Date
8/14/24
Completion Date
7/31/29
Dollars Obligated
$477K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $431,004 to the University of California, Davis to investigate the fundamental mechanisms underlying the process of "trogocytosis" between the pathogenic amoeba Entamoeba histolytica and human cells. The research aims to elucidate the dynamic interplay between the amoeba and human cells during this...
This Project Grant award, valued at $792,687.00 and issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to define the structural features of sialoglycans necessary for influenza A virus (IAV) infection and adaptation across various host species. The key activities under this award include: 1) using CRISPR/Cas9 techniques to truncate different types of sialoglycans in human lung...
This Project Grant award of $536,871 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to identify pan-arenavirus sites of vulnerability through machine learning and artificial neural network molecular screening of small molecules against arenavirus glycoprotein complexes (GPC) and RNA polymerases (RNAP). The proposed research seeks to define molecular specificities and commonalities across...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $318,085 to support research on the role of antibodies in controlling virus infections through Fc-dependent mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytolysis (CDC). The research aims to elucidate the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $453,750 to Tufts University School of Medicine to study how certain bacteriophages (viruses that infect bacteria) evade the protective mechanisms of bacteria, including some deadly pathogens like Vibrio cholerae. The project aims to determine the counter-defense mechanisms used by these phages and identify the...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $303,076 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Washington. The grant, awarded on November 5, 2024, supports research to understand how viruses evade and co-opt the body's innate immune defenses, specifically focusing on how enteric viruses develop resistance to antimicrobial peptides called defensins. The research aims to elucidate the molecular,...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $254,250 to New York University (NYU) from July 1, 2025 to June 30, 2027. The funding supports research to understand how pathogenic alphaviruses, such as chikungunya virus, infect and spread through human microvascular endothelial cells. The research aims to identify viral and host factors that restrict alphavirus...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research on manipulating the DNA damage response and proteome on viral genomes during herpes simplex virus (HSV) infection. The $651,832 award, with a project period from November 2024 to October 2029, will enable researchers at The Children's Hospital of Philadelphia to conduct a multi-modal proteomic...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $683,995.00 to fund research to develop novel therapeutics targeting human cytomegalovirus (CMV) infections. The research focuses on characterizing the mechanism of action and optimizing a series of N-arylpyrimidinamine (NAPA) compounds that demonstrated potent anti-CMV activity in a high-throughput screening assay....
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $626,423 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Texas Medical Branch at Galveston (UTMB). The funding will support research to explore the dependence of arenaviruses on the metabolism of the monosaccharides D-glucose and D-mannose, with the goal of developing carbohydrate antimetabolite compounds as potential pan-arenavirus therapeutics. Specifically,...